Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
BioNTech plans a spin-off
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
Roche flunks its first-line degrader test
Persevera is a bust, but Roche hasn’t given up on the front line.
Like Sanofi, German Merck keeps the CEACAM5 faith
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Double trouble for Incyte in KRAS
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
The month ahead: March’s upcoming events
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
ASCO-GU – Flare hits an “undruggable” target
But biomarker enrichment and toxicity remain key for FX-909.
